Bontemps F, Van den Berghe G
Laboratory of Physiological Chemistry, International Institute of Cellular and Molecular Pathology, Brussels, Belgium.
Cancer Res. 1989 Sep 15;49(18):4983-9.
The mechanism of the depletion of ATP, recorded in the erythrocytes of adenosine deaminase-deficient children and of leukemia patients treated with deoxycoformycin, was investigated in normal human erythrocytes treated with this inhibitor of adenosine deaminase. Deoxyadenosine, which accumulates in both clinical conditions, provoked a dose-dependent accumulation of dATP, depletion of ATP, and increases in the production of inosine plus hypoxanthine. Concomitantly, there was an increase of AMP and IMP, but not of adenosine, indicating that catabolism proceeded by way of AMP deaminase. A series of nucleoside analogues (9-beta-D-arabinofuranosyladenine, N6-methyladenosine, 6-methylmercaptopurine ribonucleoside, tubercidin, ribavirin, and N-1-ribosyl-5-aminoimidazole-4-carboxamide riboside) also stimulated adenine nucleotide catabolism and increased AMP and IMP to various extents. The effects of deoxyadenosine and of the nucleoside analogues were prevented by 5'-iodotubercidin, an inhibitor of adenosine kinase. Strikingly, they were reversed if the inhibitor was added after the accumulation of nucleotide analogues and initiation of adenine nucleotide catabolism. Further analyses revealed linear relationships between the rate of phosphorylation of deoxyadenosine and nucleoside analogues and the increase in AMP and between the elevation of the latter above a threshold concentration of 10 microM and the rate of adenine nucleotide catabolism. Kinetic studies with purified erythrocytic AMP deaminase, at physiological concentrations of its effectors, showed that the enzyme is nearly inactive up to 10 microM AMP and increases in activity above this threshold. We conclude that the main mechanism whereby deoxyadenosine and nucleoside analogues stimulate catabolism of adenine nucleotides by way of AMP deaminase in erythrocytes is elevation of AMP, secondary to the phosphorylation of the nucleosides.
在使用这种腺苷脱氨酶抑制剂处理的正常人红细胞中,研究了腺苷脱氨酶缺乏儿童和接受脱氧助间型霉素治疗的白血病患者红细胞中记录的ATP消耗机制。在这两种临床情况下积累的脱氧腺苷,引发了dATP的剂量依赖性积累、ATP的消耗以及肌苷加次黄嘌呤产量的增加。同时,AMP和IMP增加,但腺苷没有增加,这表明分解代谢是通过AMP脱氨酶进行的。一系列核苷类似物(9-β-D-阿拉伯呋喃糖基腺嘌呤、N6-甲基腺苷、6-甲基巯基嘌呤核糖核苷、杀结核菌素、利巴韦林和N-1-核糖基-5-氨基咪唑-4-甲酰胺核糖核苷)也刺激了腺嘌呤核苷酸分解代谢,并不同程度地增加了AMP和IMP。腺苷激酶抑制剂5'-碘杀结核菌素可阻止脱氧腺苷和核苷类似物的作用。令人惊讶的是,如果在核苷酸类似物积累和腺嘌呤核苷酸分解代谢开始后加入抑制剂,其作用会被逆转。进一步分析显示,脱氧腺苷和核苷类似物的磷酸化速率与AMP的增加之间以及后者升高到10μM的阈值浓度以上与腺嘌呤核苷酸分解代谢速率之间存在线性关系。在其效应物的生理浓度下,用纯化的红细胞AMP脱氨酶进行的动力学研究表明,该酶在高达10μM的AMP时几乎无活性,在此阈值以上活性增加。我们得出结论,脱氧腺苷和核苷类似物通过AMP脱氨酶刺激红细胞中腺嘌呤核苷酸分解代谢的主要机制是核苷磷酸化导致的AMP升高。